News | Heart Failure | March 08, 2022

Addressing the Difficulty of Diagnosing Heart Attacks After Heart Surgery

UTSW faculty argue that more innovation is needed to determine how best to interpret troponin levels after heart surgery

James de Lemos, M.D.

James de Lemos, M.D. Credit: UT Southwestern Medical Center


Mrach 8, 2022 – Diagnosing heart attacks after heart surgery remains difficult due to shortcomings of current diagnostic tools when applied to postoperative patients, including the electrocardiogram and blood tests to detect levels of cardiac troponins, according to an editorial in the New England Journal of Medicine (NEJM) written by two UT Southwestern faculty members.

A new study in NEJM details post-surgery attempts to identify abnormal levels of heart muscle proteins called troponins. But the article written by Cardiology Professor James de Lemos, M.D., and Michael Jessen, M.D., Professor and Chair of Cardiovascular and Thoracic Surgery, points out that the new tests lack clarity, and the use of many different assays to measure troponins makes clinical application of the findings problematic. They argue that more innovation is needed to determine how best to interpret troponin levels after heart surgery. To improve surgical outcomes, it will be necessary to sort out high troponin levels that are due to specific and modifiable complications of surgery from those due to the normal manipulation of the heart during the operation.

Drs. de Lemos and Jessen were invited to write the editorial because of Dr. de Lemos’ distinguished research into high-sensitivity troponins and Dr. Jessen’s national expertise in surgical techniques designed to improve safety and outcomes of heart surgery.

Dr. de Lemos helps lead UT Southwestern’s effort to incorporate high-sensitivity troponin assays to better diagnose heart attacks. In a multidisciplinary collaboration involving emergency medicine, lab medicine, cardiology, and hospitalist medicine, UTSW was among the first U.S. institutions to implement these tests. They have shown that implementing high-sensitivity troponin tests together with an accelerated diagnostic pathway enables clinicians to safely exclude heart attacks in an hour in most patients who arrive at the Emergency Department (ED) with chest pain. This shortens time spent in the hospital and reduces Emergency Department crowding.

Dr. de Lemos has published in JAMA about the prevalence of detectable levels of cardiac troponin Ta novel protocol for minimizing ED dwell times, and associations of high-sensitivity troponin with outcomes after intensive blood pressure lowering.

Under Dr. Jessen’s leadership, UT Southwestern achieves elite levels of patient care in cardiac surgery. According to data from the Society of Thoracic Surgeons Adult Cardiac Surgery Database, UTSW performed 269 aortic valve operations from July 2018 to June 2021 with a mortality rate of 0.74% – better than 94% of all heart surgery programs in the U.S. For surgeries to repair the mitral valve, UTSW results are better than 97% of all programs.

Dr. Jessen was part of the American College of Cardiology Foundation/American Heart Association Task Force that produced the 2011 Guideline for Coronary Artery Bypass Graft Surgery.

U.S. News and World Report ranks UT Southwestern as the No.1 hospital in Texas for cardiology and heart surgery and No.11 in the nation. 

Dr. de Lemos holds the Sweetheart Ball-Kern Wildenthal, M.D., Ph.D. Distinguished Chair in Cardiology. Dr. Jessen holds the Frank M. Ryburn, Jr., Distinguished Chair in Cardiothoracic Surgery and Transplantation. 

Conflict of interest disclosures are made in the manuscript.

For more information: https://www.nejm.org/


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now